Duovir-N Tablets - Active Ingredient And Product Information
Duovir-N Tablets are a combination of three drugs namely zidovudine, lamivudine and Nevirapine that are commonly used in the management of the Human Immunodeficiency Virus (HIV) infection. Zidovudine and lamivudine belong to the nucleoside analogue class of antiretroviral drugs which act by terminating the growth of the DNA chain and inhibiting the reverse transcriptase (RT) of HIV. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). It acts by directly inhibiting Reverse Transcriptase.
The active ingredients contained in Duovir-N Tablets is zidovudine, lamivudine and Nevirapine.
Duovir-N Preparations
Duovir-N is available as tablets which have a combination of three drugs Lamivudine, Zidovudine and Nevirapine . Each film coated tablet contains Lamivudine 150 mg, Zidovudine 300 mg BP and Nevirapine 200 mg
Duovir-N - Storage Requirements
Duovir-N are to be stored at room temperature (15°C to 30°C). Store away from heat, moisture, and light.
Duovir-N - Uses
Duovir-N Tablets are used for the treatment of HIV infection, once patients have been stabilized on the maintenance regimen of nevirapine 200 mg twice a day, and have demonstrated adequate tolerability to nevirapine.
Duovir-N - Dosage
The recommended adult dosage of Duovir-N is One tablet twice daily.
Duovir-N - Contraindications
Duovir-N Tablets are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (eg, anaphylaxis, Stevens-Johnson syndrome) to zidovudine, lamivudine and Nevirapine or any inactive components of the product. It is also contraindicated in patients with moderate or severe (Childs Pugh Class B or C, respectively) hepatic impairment.
Duovir-N - Warnings and Precautions
Hepatotoxicity and Hepatic Impairment
Severe, life threatening and, in some cases, fatal hepatotoxicity, including fulminant and cholestatic hepatitis, hepatic necrosis and hepatic failure, have been reported in patients treated with nevirapine.
Skin Reactions
Severe and life-threatening skin reactions, including fatal cases, have been reported with nevirapine treatment, occurring most frequently during the first 6 weeks of therapy. These have included cases of Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity reactions characterized by rash, constitutional findings and organ dysfunction, including hepatic failure.
Resistance
Nevirapine must not be used as a single agent to treat HIV or added on as a sole agent to a failing regimen. As with all other NNRTIs, resistant virus emerges rapidly when nevirapine is administered as monotherapy.
Immune Reconstitution Syndrome
Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including lamivudine, zidovudine and nevirapine. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections.
Side Effects Of Duovir-N
The most common side effects of Duovir-N are
Body as a Whole
Headache ,Malaise and fatigue, Fever or chills
Digestive
Nausea, Diarrhea, Nausea and vomiting, Anorexia and/or decreased appetite, Abdominal pain, Abdominal cramps, Dyspepsia
Nervous System
Neuropathy, Insomnia and other sleep disorders, Dizziness, Depressive disorders
Respiratory
Nasal signs and symptoms, Cough
Skin
Skin rashes
Musculoskeletal
Musculoskeletal pain, Myalgia, Arthralgia
